COVID-19 Diagnostics
On March 11, 2020, the World Health Organization declared a global pandemic arising from corona virus disease – 19 (COVID-19). Some of the first cases that began from Wuhan (China) in end of 2019 have reached almost 4,347,935 cases causing 297,241 deaths, worldwide (As of 15 May 2020). On one hand the healthcare systems globally have been struggling to manage the COVID-19 patient population and the researchers are racing to find a solution to this problem; while on the other hand, the economic impacts are felt across other sectors. Globally, there has been GDP decline, increase in unemployment rates, and increase in inflation rates. For instance, in the U.S., by end of April 2020, more than 3.8 million people were laid off and roughly 30 million people filed for jobless aid. In the U.K., around 7.5 million people are covered under furlough scheme, a government’s job retention scheme (May 2012). Top countries to have the most number of confirmed cases (As of 15 May 2020) included the U.S., Spain, Russia, the U.K., Italy, Brazil, France, Germany, Turkey, and Iran. Top countries to have most number of deaths due to COVID-19 (as of 15 May 2020) include the U.S., the U.K., Italy, France, Spain, Brazil, Germany, Iran, Turkey, and India.
Key Players

Some of the key players involved in the COVID-19 product development include Roche Holding AG (Switzerland), Thermo Fisher Scientific, Inc. (U.S.), Abbott Laboratories (U.S.), Becton, Dickinson and Company (U.S.), AbbVie Corporation (U.S.), Gilead Sciences, Inc. (U.S.), Eli Lilly and Company (U.S.), Moderna, Inc. (U.S.), Novavax, Inc. (U.S.), Medicago, Inc. (U.S.), Inovio Pharmaceuticals, Inc. (U.S.), GlaxoSmithKline (U.K.), Sanofi S.A. (France), Johnson & Johnson (U.S.), Sorrento Therapeutics, Inc. (U.S.), AstraZeneca Plc (U.K.), Pfizer, Inc. (U.S.), CTI Biopharma Corporation (U.S.), OncoImmune, Inc. (U.S.), Athersys, Inc. (U.S.), Celularity, Inc. (U.S.), Pluristem Therapeutics (Israel), Takeda Pharmaceuticals Company Ltd (Japan), among others.

Scope of the Report:

COVID-19 Product Pipeline

Diagnosis
PCR Testing
Antibody Testing
Treatment
Vaccines
Immunotherapy
Antiviral
Cell-based Therapy
Other Therapies
COVID-19: Impact on Healthcare Industry

Diagnostics
Rapid Test Kits
PCR / Rapid Antigen Testing / Nucleic Acid-Based Tests
Advantages Offered by PCR Testing in COVID -19 Diagnosis
Restraints
Key Companies
Antibody Testing / Serological Testing
Advantages Over Molecular Tests
Use of Antibody Testing for Herd Immunity Analysis and Easing Lock-Down
Restraints
Key Companies
Therapies
Vaccines
Immunotherapies (Antibodies)
Monoclonal Antibody
T-Cell Therapy
Potential Game Changers: Antibodies
Ilaris (Canakinumab)
Sylvant (Siltuximab)
Lenzilumab
Ultomiris (Ravulizumab-Cwvz)
Tocilizumab
Anti-Virals
Potential Game Changers
Chloroquine and Hydroxychloroquine (HCQ)
Remdesivir
Cell-Based Therapies
Other Therapies
Plasma Therapy
Devices
COVID-19 Industry Impact Assessment, by Geography

North America
Europe
Asia-Pacific (APAC)
Rest of the World (RoW)
𝑫𝒐𝒘𝒏𝒍𝒐𝒂𝒅 𝑺𝒂𝒎𝒑𝒍𝒆 𝑹𝒆𝒑𝒐𝒓𝒕 @
https://www.meticulousresearch.com/download-sample-report/cp_id=5098?utm_source=sb&utm_medium=Social&utm_campaign=Product&utm_content=13-12-2022